IMMUNOVANT, INC. — Income Charts
1 years of history · ending 2024-03-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$25M
R&D
$213M
D&A
$231K
EBITDA
$231K
Interest Expense
$25M
Pretax Income
$-259M
Tax Provision
$567K
Net Income
$-259M
Net Margin
-1039.5%
Effective Tax Rate
-0.2%
Deferred Tax Assets
$347K
Deferred Tax Liabilities
$74K
DTA Valuation Allowance
$141M
Tax Credit Carryforwards
$21M
NOL Carryforwards
$98M
ETR (Continuing Operations)
-0.2%
Operating Lease Cost
$1M
Revenue YoY Variation
229.2%